Alan Duncan Robertson

Title: Alan Duncan Robertson: Innovator in Neuromuscular and Neuroinflammatory Treatments

Introduction

Alan Duncan Robertson is a notable inventor based in Warawee, Australia. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target various neuromuscular and neuroinflammatory diseases. His innovative work has the potential to improve the quality of life for both humans and animals.

Latest Patents

Robertson holds a patent for "Haloallylamine dual amine oxidase inhibitors." This invention relates to novel compounds capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are particularly useful in treating a variety of neuromuscular diseases, such as muscular dystrophies, as well as neuroinflammatory diseases affecting both peripheral and central nervous systems in human subjects, pets, and livestock. The patent also encompasses pharmaceutical compositions containing these compounds and various applications thereof.

Career Highlights

Robertson is associated with Syntara Limited, where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on addressing unmet medical needs in the field of neurology.

Collaborations

Some of his notable coworkers include Alison Dorothy Findlay and Alberto Buson. Their collaborative efforts contribute to the ongoing research and development initiatives at Syntara Limited.

Conclusion

Alan Duncan Robertson's contributions to the field of pharmaceutical sciences, particularly through his patent on dual amine oxidase inhibitors, highlight his role as an innovator in treating neuromuscular and neuroinflammatory diseases. His work continues to pave the way for advancements in medical treatments.